This is a demo store. No orders will be fulfilled.

Lendalizumab (anti-Complement C5) - Primary antibody, specific to C5, Human IgG2SA

    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
  • Host species: Human
  • Reactive species: Human
  • Isotype: Human IgG2SA
  • Conjugation: Unconjugated
In stock
Item Number
Ab191930
Grouped product items
SKU Size
Availability
Price Qty
Ab191930-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$109.90
Ab191930-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$519.90
Ab191930-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,299.90
Ab191930-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,079.90

Purity≥95% (SDS-PAGE&SEC-HPLC); Endotoxin Level<1.0 EU/mg; Human IgG2SA; CHO; ELISA, Flow Cytometry, Functional assay, Animal Model; Unconjugated

Basic Description

Product Name Lendalizumab (anti-Complement C5) - Primary antibody, specific to C5, Human IgG2SA
Synonyms Anaphylatoxin C5a analog antibody | C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4 antibody | C5 antibody | C5a anaphylatoxin antibody | C5a antibody | C5b antibody | CO5_HUMAN antibody | Complement C5 alpha'' chain antibody | Complemen
Specifications & Purity Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA
Biochemical and Physiological Mechanisms Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex i
Host species Human
Specificity C5
Conjugation Unconjugated
Grade Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Product Description

Lendalizumab (anti-Complement C5) is a proprietary antibody that targets the complement protein C5a with potential immunomodulating and anti-inflammatory activities.

Product Properties

Isotype Human IgG2SA
Light Chain Type kappa
SDS-PAGE 145 kDa
Purification Method Protein A purified
Concentration See COA
Storage Temp Store at -80°C,Avoid repeated freezing and thawing
Shipped In Ice chest + Ice pads
Stability And Storage Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.
CAS 2210314-30-8

Associated Targets(Human)

C5 Tclin Complement C5 (0 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

Mechanisms of Action

Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References

Images

Lendalizumab (anti-Complement C5) (Ab191930) - ELISA
Immobilized Recombinant Human Complement C5 protein at 2.0 μg/mL can bind Lendalizumab (anti-Complement C5) (Ab191930) with the EC₅₀ of 2.58 ng/mL.

Lendalizumab (anti-Complement C5) (Ab191930) - SEC
The purity of Lendalizumab (anti-Complement C5) (Ab191930) is more than 95% verified by HPLC.

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Alternative Products

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.